Results 201 to 210 of about 105,931 (293)

Pre‐analytical guidelines for blood and CSF Biomarkers 2025: Recommendations from the NACC ADRC Biofluid Biomarker Best Practices Workgroup

open access: yesAlzheimer's &Dementia, Volume 22, Issue 5, May 2026.
Abstract The Biofluid Biomarkers Best Practices Workgroup of the National Alzheimer's Coordinating Center–Alzheimer's Disease Research Center (ADRC) Biomarker Core Steering Committee was convened to update pre‐analytical handling guidelines for biofluid biomarkers, focusing on cerebrospinal fluid (CSF) and blood.
Timothy E. Van Meter   +21 more
wiley   +1 more source

The impact of learning about financial compensation on enrollment in Alzheimer's disease longitudinal research

open access: yesAlzheimer's &Dementia, Volume 22, Issue 5, May 2026.
Abstract INTRODUCTION Recruitment and retention remains a major challenge in Alzheimer's disease research. This study examined the impact of describing potential financial compensation during recruitment on participant enrollment to a longitudinal cohort. METHODS Participant recruitment calls (N = 337) were randomized to either a compensation‐mentioned
Matthew Gabel   +6 more
wiley   +1 more source

Watching the eye with Mars in sight

open access: yes
Experimental Physiology, EarlyView.
Peter zu Eulenburg   +2 more
wiley   +1 more source

Integrating polygenic and transcriptional risk scores for detecting Alzheimer's disease

open access: yesAlzheimer's &Dementia, Volume 22, Issue 5, May 2026.
Abstract INTRODUCTION Early detection of Alzheimer's disease (AD) is essential, yet existing biomarkers are invasive or costly. Polygenic risk scores (PRS) and transcriptional risk scores (TRS) may offer accessible alternatives, but their combined predictive performance remains understudied.
Jiyun Hwang   +10 more
wiley   +1 more source

Usage and positivity rates of Alzheimer's disease biomarkers in a memory clinic

open access: yesAlzheimer's &Dementia, Volume 22, Issue 5, May 2026.
Abstract INTRODUCTION Usage of biomarker tests for Alzheimer's disease pathology and rates of positivity were assessed at the Washington University Memory Diagnostic Center. METHODS Patients who underwent at least one biomarker test for clinical purposes between June 2021 and March 2025 were included (n = 1136). Data were retrospectively extracted from
Anna Hofmann   +20 more
wiley   +1 more source

Effects of α‐synuclein pathology on synaptic dysfunction and clinical outcomes in normal aging

open access: yesAlzheimer's &Dementia, Volume 22, Issue 5, May 2026.
Abstract INTRODUCTION α‐Synuclein is the hallmark pathology of Parkinson's disease and dementia with Lewy bodies, described together as Lewy body disease (LBD). We investigated effects of α‐syn biomarker positivity in clinically unimpaired (CU) individuals.
Joseph R. Winer   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy